News

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...
Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors Mon Nov 28, 2011 1:02am EST Addex Pharmaceuticals / Addex ...
While semaglutide mimics GLP-1 (glucagon-like peptide), a hormone that suppresses appetite and regulates metabolism, tirzepatide adds an analog of another gastric hormone, GIP (gastric inhibitory ...
Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...
Novo Nordisk and Septerna will jointly initiate four preclinical development programmes, targeting well-established metabolic receptors for glucagon-like peptide 1 (GLP-1), gastric inhibitory ...
The Mounjaro-like anti-obesity prescription drug Zepbound is now available at pharmacies. Health experts provide clear answers to common questions about the newest GLP-1 weight loss medication.
Inhibitory effect of C-type natriuretic peptide on spontaneous contraction in gastric antral circular smooth muscle of rat. Acta Pharmacol Sin 2003; 24 : 1021–6. CAS PubMed Google Scholar ...
AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.
NM-136 works by targeting an obesity-related hormone called gastric inhibitory peptide (GLP). Its second drug candidate, vurolenatide, belongs to a class of drugs known as GLP-1 inhibitors, which ...
We are planning to initiate human Ph0 imaging studies of 64Cu-PD-29875, highly-selective peptide-RI conjugate against Claudin 18.2, in 2025.